biotricity inc - BTCY

BTCY

Close Chg Chg %
0.09 0.00 0.00%

Open Market

0.09

0.00 (0.00%)

Volume: 3.92K

Last Updated:

Sep 9, 2026, 3:46 PM EDT

Company Overview: biotricity inc - BTCY

BTCY Key Data

Open

$0.09

Day Range

0.09 - 0.09

52 Week Range

0.09 - 0.75

Market Cap

$1.81M

Shares Outstanding

20.07M

Public Float

9.35M

Beta

1.17

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.13

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

11.73K

 

BTCY Performance

1 Week
 
-10.00%
 
1 Month
 
-22.41%
 
3 Months
 
-25.00%
 
1 Year
 
-87.59%
 
5 Years
 
-99.53%
 

BTCY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About biotricity inc - BTCY

Biotricity, Inc. is a medical technology company, which engages in biometric data monitoring solutions. Its products include Bioflux, Biocore, Bioheart, Biokit, and Biocare. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on January 25, 2011 and is headquartered in Redwood City, CA.

BTCY At a Glance

Biotricity, Inc.
203 Redwood Shores Parkway
Redwood City, California 94065
Phone 1-800-590-4155 Revenue 16.00M
Industry Packaged Software Net Income -2,404,139.00
Sector Technology Services 2026 Sales Growth 16.011%
Fiscal Year-end 03 / 2027 Employees 46
View SEC Filings

BTCY Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.403
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 16.215
Enterprise Value to Sales 2.192
Total Debt to Enterprise Value 0.772

BTCY Efficiency

Revenue/Employee 347,787.804
Income Per Employee -52,263.891
Receivables Turnover 5.455
Total Asset Turnover 2.647

BTCY Liquidity

Current Ratio 0.158
Quick Ratio 0.122
Cash Ratio 0.004

BTCY Profitability

Gross Margin 80.939
Operating Margin 10.571
Pretax Margin -15.028
Net Margin -15.028
Return on Assets -39.779
Return on Equity N/A
Return on Total Capital 40.757
Return on Invested Capital N/A

BTCY Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -458.808
Total Debt to Total Assets 419.822
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -14.763
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biotricity Inc - BTCY

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
9.64M 12.06M 13.79M 16.00M
Sales Growth
+26.00% +25.15% +14.32% +16.01%
Cost of Goods Sold (COGS) incl D&A
4.20M 3.71M 3.23M 3.05M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
346.26K 371.85K 415.49K 471.79K
Depreciation
346.26K 371.85K 415.49K 471.79K
Amortization of Intangibles
- - - -
-
COGS Growth
+36.26% -11.67% -12.98% -5.47%
Gross Income
5.44M 8.36M 10.56M 12.95M
Gross Income Growth
+19.08% +53.55% +26.43% +22.57%
Gross Profit Margin
+56.46% +69.27% +76.61% +80.94%
2023 2024 2025 2026 5-year trend
SG&A Expense
20.85M 17.18M 13.01M 11.26M
Research & Development
3.23M 2.57M 2.16M 2.76M
Other SG&A
17.62M 14.61M 10.86M 8.49M
SGA Growth
-5.41% -17.59% -24.27% -13.49%
Other Operating Expense
- - - -
-
Unusual Expense
554.99K (28.32K) 691.79K 147.51K
EBIT after Unusual Expense
(15.96M) (8.80M) (3.14M) 1.54M
Non Operating Income/Expense
(110.82K) (102.61K) (78.57K) 159.98K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.58M 5.19M 5.20M 4.11M
Interest Expense Growth
-73.73% +101.03% +0.20% -21.03%
Gross Interest Expense
2.58M 5.19M 5.20M 4.11M
Interest Capitalized
- - - -
-
Pretax Income
(18.66M) (14.09M) (8.42M) (2.40M)
Pretax Income Growth
+35.95% +24.46% +40.25% +71.45%
Pretax Margin
-193.57% -116.84% -61.07% -15.03%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(18.66M) (14.09M) (8.42M) (2.40M)
Minority Interest Expense
- - - -
-
Net Income
(18.66M) (14.09M) (8.42M) (2.40M)
Net Income Growth
+35.95% +24.46% +40.25% +71.45%
Net Margin Growth
-193.57% -116.84% -61.07% -15.03%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(18.66M) (14.09M) (8.42M) (2.40M)
Preferred Dividends
875.54K 834.68K 3.52M 724.32K
Net Income Available to Common
(19.53M) (14.93M) (11.94M) (3.13M)
EPS (Basic)
-2.2557 -1.6603 -0.5548 -0.1146
EPS (Basic) Growth
+43.46% +26.40% +66.58% +79.34%
Basic Shares Outstanding
8.66M 8.99M 21.52M 27.30M
EPS (Diluted)
-2.2557 -1.6603 -0.5548 -0.1146
EPS (Diluted) Growth
+43.46% +26.40% +66.58% +79.34%
Diluted Shares Outstanding
8.66M 8.99M 21.52M 27.30M
EBITDA
(15.06M) (8.46M) (2.03M) 2.16M
EBITDA Growth
+13.45% +43.86% +75.95% +206.37%
EBITDA Margin
-156.28% -70.10% -14.75% +13.52%

Biotricity Inc in the News